These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 31125418)
1. Defining EGFR amplification status for clinical trial inclusion. French PJ; Eoli M; Sepulveda JM; de Heer I; Kros JM; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Weller M; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; van den Bent M Neuro Oncol; 2019 Oct; 21(10):1263-1272. PubMed ID: 31125418 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Biomarker Assays for Lassman AB; Roberts-Rapp L; Sokolova I; Song M; Pestova E; Kular R; Mullen C; Zha Z; Lu X; Gomez E; Bhathena A; Maag D; Kumthekar P; Gan HK; Scott AM; Guseva M; Holen KD; Ansell PJ; van den Bent MJ Clin Cancer Res; 2019 Jun; 25(11):3259-3265. PubMed ID: 30796037 [TBL] [Abstract][Full Text] [Related]
3. Detecting EGFR gene amplification using a fluorescence in situ hybridization platform based on digital microfluidics. Shen C; Zhan C; Tong Z; Yin H; Hui J; Qiu S; Li Q; Xu X; Ma H; Wu Z; Shi N; Mao H Talanta; 2024 Mar; 269():125444. PubMed ID: 38042143 [TBL] [Abstract][Full Text] [Related]
4. Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods. Lih CJ; Si H; Das B; Harrington RD; Harper KN; Sims DJ; McGregor PM; Camalier CE; Kayserian AY; Williams PM; He HJ; Almeida JL; Lund SP; Choquette S; Cole KD J Mol Diagn; 2016 Sep; 18(5):753-761. PubMed ID: 27455875 [TBL] [Abstract][Full Text] [Related]
8. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Lassman AB; Aldape KD; Ansell PJ; Bain E; Curran WJ; Eoli M; French PJ; Kinoshita M; Looman J; Mehta M; Muragaki Y; Narita Y; Ocampo C; Roberts-Rapp L; Song M; Vogelbaum MA; Walenkamp AME; Wang TJC; Zhang P; van den Bent MJ J Neurooncol; 2019 Aug; 144(1):205-210. PubMed ID: 31273577 [TBL] [Abstract][Full Text] [Related]
10. A troublesome burden, the amplification of EGFR in glioblastoma! Lobbous M; Nabors LB Neuro Oncol; 2020 May; 22(5):594-595. PubMed ID: 32144420 [No Abstract] [Full Text] [Related]
11. Wu S; Gao F; Zheng S; Zhang C; Martinez-Ledesma E; Ezhilarasan R; Ding J; Li X; Feng N; Multani A; Sulman EP; Verhaak RG; de Groot JF; Heffernan TP; Yung WKA; Koul D Clin Cancer Res; 2020 Mar; 26(6):1395-1407. PubMed ID: 31852834 [TBL] [Abstract][Full Text] [Related]
12. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
14. EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization. Wilcock DM; Goold E; Zuromski LM; Davidson C; Mao Q; Sirohi D J Neuropathol Exp Neurol; 2024 Apr; 83(5):338-344. PubMed ID: 38605523 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects. Penkova A; Kuziakova O; Gulaia V; Tiasto V; Goncharov NV; Lanskikh D; Zhmenia V; Baklanov I; Farniev V; Kumeiko V Front Mol Biosci; 2023; 10():1216102. PubMed ID: 37908227 [TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype. Sohn B; Park K; Ahn SS; Park YW; Choi SH; Kang SG; Kim SH; Chang JH; Lee SK J Neurooncol; 2023 Sep; 164(2):341-351. PubMed ID: 37689596 [TBL] [Abstract][Full Text] [Related]
17. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Sahm F; Brandner S; Bertero L; Capper D; French PJ; Figarella-Branger D; Giangaspero F; Haberler C; Hegi ME; Kristensen BW; Kurian KM; Preusser M; Tops BBJ; van den Bent M; Wick W; Reifenberger G; Wesseling P Neuro Oncol; 2023 Oct; 25(10):1731-1749. PubMed ID: 37279174 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of resistant mechanisms in an Li Y; Xu Z; Xie T; Xing P; Ying J; Li J Front Oncol; 2022; 12():937282. PubMed ID: 36033496 [No Abstract] [Full Text] [Related]
19. Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma. Suzuki H; Ono T; Koyota S; Takahashi M; Sugai T; Nanjo H; Shimizu H J Neurooncol; 2022 Sep; 159(2):397-408. PubMed ID: 35779193 [TBL] [Abstract][Full Text] [Related]